Weight loss shots

Semaglutide and tirzepatide are category of medication called GLP-1 agonists.  They are weekly injections initially designed for the treatment of type 2 diabetes but have been found to be highly effective in nondiabetics for the management of obesity.  By slowing down how rapidly the stomach moves, it slows the absorption of nutrients, keeping the blood sugar lower and preventing the spikes in insulin that store calories we eat into the fat cells.  Because the stomach will empty more slowly, they create a sensation of fullness so patients are not hungry, and feel satisfied more quickly.  

There have been advantages seen as a result.  For semaglutide patients experience a minimum of 15% weight loss and for tirzepitide 23.5% (over a year advancing to the maximum dose).  Cardiovascular benefits have also been seen with reductions in cholesterol and blood pressure as the weight drops.  

Semaglutide is the generic name for Wegovy (weight loss) and Ozempic (diabetes).

Tirzepatide is the generic name for Zepbound (weight loss) and Mounjaro (diabetes).  In addition to the GLP-1 agonist it has a second component called the GIP agonist which also prevents the metabolic triggers that allow caloric storage into fat.  

Put simply, these medications slow how quickly the stomach empties, allow patients to feel full faster and longer, and reduce our calories from being stored into fat.  With dietary changes, monitoring by a health care provider, and lifestyle changes, healthy weights can be achieved in most patients.